1.Two Cases of Myeloproliferative Neoplasm with a Concurrent JAK2V617F Mutation and BCR/ABL Translocation without Chronic Myelogenous Leukemia Phenotype Acquisition during Hydroxyurea Treatment.
Sang Hyuk PARK ; Hyun Sook CHI ; Young Uk CHO ; Seongsoo JANG ; Chan Jeoung PARK ; Dae Young KIM ; Je Hwan LEE ; Kyoo Hyung LEE
Annals of Laboratory Medicine 2013;33(3):229-232
No abstract available.
Adult
;
Alleles
;
Fusion Proteins, bcr-abl/*genetics
;
Heterozygote
;
Humans
;
Hydroxyurea/*therapeutic use
;
Janus Kinase 2/*genetics
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis
;
Leukocytes, Mononuclear/pathology
;
Leukocytosis/diagnosis
;
Male
;
Middle Aged
;
Mutation
;
Myeloproliferative Disorders/drug therapy/*genetics
;
Phenotype
;
Splenomegaly/diagnosis
;
Thrombocytosis/diagnosis
;
Translocation, Genetic
2.A Rare Case of Chronic Myelogenous Leukemia and Plasma Cell Myeloma in the Same Patient.
Sunhyun AHN ; Joon Seong PARK ; Jae Ho HAN ; Sung Ran CHO
Annals of Laboratory Medicine 2015;35(3):370-372
No abstract available.
Aged
;
Antineoplastic Agents/therapeutic use
;
Bone Marrow/pathology
;
Fusion Proteins, bcr-abl/genetics/metabolism
;
Humans
;
Imatinib Mesylate/therapeutic use
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications/*diagnosis/drug therapy
;
Leukocyte Count
;
Male
;
Multiple Myeloma/complications/*diagnosis/drug therapy
;
Platelet Count
;
Polymerase Chain Reaction
;
Thrombocytosis/etiology
3.A Case of Isolated Lymphoblastic Relapse of the Central Nervous System in a Patient with Chronic Myelogenous Leukemia Treated with Imatinib.
Mi Jung PARK ; Pil Whan PARK ; Yiel Hea SEO ; Kyung Hee KIM ; Ja Young SEO ; Ji Hun JEONG ; Moon Jin KIM ; Jin Woo JEONG ; Jeong Yeal AHN ; Jinny PARK
Annals of Laboratory Medicine 2014;34(3):247-251
No abstract available.
Antineoplastic Agents/*therapeutic use
;
Benzamides/*therapeutic use
;
Central Nervous System Neoplasms/*diagnosis
;
Fusion Proteins, bcr-abl/genetics
;
Humans
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy
;
Leukocytes/metabolism/pathology
;
Male
;
Middle Aged
;
Neoplasm Recurrence, Local
;
Piperazines/*therapeutic use
;
Pyrimidines/*therapeutic use
4.A Case of t(3;3)(q21;q26.2) Associated with Severe Multilineage Dysplasia and Multi-drug Resistance in Blastic Crisis of Chronic Myelogenous Leukemia.
Sun Ah LEE ; Jihyang LIM ; Myungshin KIM ; Yonggoo KIM ; Kyungja HAN
The Korean Journal of Laboratory Medicine 2010;30(6):595-599
The t(3;3)(q21;q26.2) is known to be mainly observed in hematologic myeloid malignancies, as a form of 3q21q26 syndrome. Cytogenetic abnormalities of 3q21q26 syndrome result in RPN1-EVI1 fusion transcripts involving ecotropic viral integration site-1 (EVI1) at 3q26.2 and ribophorin I (RPN1) at 3q21, and the fusion transcripts play an important role in leukemogenesis and disease progression. They are usually associated with dysplasia, especially of megakaryocytes. Patients with these cytogenetic abnormalities show extremely poor prognosis even with aggressive anti-leukemic therapy. We report a case of blastic crisis of CML with both t(3;3)(q21;q26.2) and t(9;22)(q34;q11.2) and associated severe multilineage dysplasia. The patient showed a poor response to imatinib, dasatinib and aggressive induction therapy. When both t(3;3)(q21;q26.2) and t(9;22)(q34;q11.2) are observed in cases of leukemia with increased blasts, they are best considered as aggressive phases of CML with t(3;3)(q21;q26.2), rather than AML with t(9;22)(q34;q11.2) by 2008 WHO classification.
Adolescent
;
Antineoplastic Agents/therapeutic use
;
Blast Crisis/*diagnosis
;
Bone Marrow Cells/pathology
;
*Chromosomes, Human, Pair 3
;
Drug Resistance, Neoplasm
;
Humans
;
Karyotyping
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*diagnosis/drug therapy/genetics
;
Male
;
Piperazines/therapeutic use
;
Pyrimidines/therapeutic use
;
Thiazoles/therapeutic use
;
*Translocation, Genetic
5.Chronic myeloid leukemia as a secondary malignancy after diffuse large B-cell lymphoma.
Ha Young LEE ; Kyung Hee LEE ; Myung Soo HYUN ; Min Kyoung KIM ; Sung Ae KOH ; Hee Soon CHO
The Korean Journal of Internal Medicine 2014;29(2):250-252
No abstract available.
Adult
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
;
Benzamides/therapeutic use
;
Bone Marrow Examination
;
Chemoradiotherapy
;
Cyclophosphamide/administration & dosage
;
Doxorubicin/administration & dosage
;
Humans
;
Karyotyping
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*diagnosis/drug therapy/genetics/pathology
;
Lymphoma, Large B-Cell, Diffuse/*diagnosis/pathology/therapy
;
Male
;
*Neoplasms, Second Primary
;
Piperazines/therapeutic use
;
Positron-Emission Tomography
;
Prednisolone/administration & dosage
;
Protein Kinase Inhibitors/therapeutic use
;
Pyrimidines/therapeutic use
;
Time Factors
;
Tomography, X-Ray Computed
;
Treatment Outcome
;
Vincristine/administration & dosage
;
Whole Body Imaging/methods